Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Baum

Showing results (131-140 of 470) with videos related to

Pageof 47
Sort By:
Clinical Nuclear Medicine|January 25, 2020
Successful Intra-arterial Peptide Receptor Radionuclide Therapy of DOTATOC-Negative High-Grade Liver Metastases of a Pancreatic Neuroendocrine Neoplasm Using 177Lu-DOTA-LM3: A Somatostatin Receptor AntagonistJingjing Zhang, Harshad R Kulkarni, Aviral Singh, et al.
Clinical Nuclear Medicine|March 27, 2020
177Lu-DOTATOC Peptide Receptor Radionuclide Therapy in a Patient With Neuroendocrine Breast Carcinoma and Breast Invasive Ductal CarcinomaQingxing Liu, Jingjing Zhang, Harshad R Kulkarni, et al.
Revue Neurologique|April 15, 2008
[Primary brain stem hemorrhage: retrospective study of 25 cases]J S Raison, G Bourbotte, T P Baum, et al.
Clinical Nuclear Medicine|April 2, 2019
Prostate-Specific Membrane Antigen Accumulation in Lower Extremity LymphedemaJingjing Zhang, Harshad R Kulkarni, Aviral Singh, et al.
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|August 25, 2012
Is there a correlation between peptide receptor radionuclide therapy-associated hematological toxicity and spleen dose?Harshad R Kulkarni, Vikas Prasad, Christiane Schuchardt, et al.
World Journal of Surgery|July 23, 1998
Late results of heterotopic autotransplantation of splenic tissue into the greater omentumT Weber, E Hanisch, R P Baum, et al.
American Journal of Nuclear Medicine and Molecular Imaging|January 1, 2014
Peptide receptor radionuclide therapy of treatment-refractory metastatic thyroid cancer using (90)Yttrium and (177)Lutetium labeled somatostatin analogs: toxicity, response and survival analysisHendra Budiawan, Ali Salavati, Harshad R Kulkarni, et al.
Clinical Nuclear Medicine|December 27, 2019
Twelve-Year Survival of a Patient With Lymph Node, Pulmonary, Bone, Cardiac and Intraspinal Metastases of a Rectal Neuroendocrine Neoplasm Treated With Peptide Receptor Radionuclide Therapy-The Value of Salvage Peptide Receptor Radionuclide TherapyJingjing Zhang, Harshad R Kulkarni, Aviral Singh, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 27, 2014
PRRT: Defining the paradigm shift to achieve standardization and individualizationLisa Bodei, Mark Kidd, Richard P Baum, et al.
International Journal of Obesity and Related Metabolic Disorders : Journal of the International Association for the Study of Obesity|June 1, 1997
Removal of endogenous leptin from the circulation by the kidneyF Cumin, H P Baum, M de Gasparo, et al.
Pageof 47

Showing results (131-140 of 470) with videos related to

Sort By:
Pageof 47
Clinical Nuclear Medicine|January 25, 2020
Successful Intra-arterial Peptide Receptor Radionuclide Therapy of DOTATOC-Negative High-Grade Liver Metastases of a Pancreatic Neuroendocrine Neoplasm Using 177Lu-DOTA-LM3: A Somatostatin Receptor AntagonistJingjing Zhang, Harshad R Kulkarni, Aviral Singh, et al.
Clinical Nuclear Medicine|March 27, 2020
177Lu-DOTATOC Peptide Receptor Radionuclide Therapy in a Patient With Neuroendocrine Breast Carcinoma and Breast Invasive Ductal CarcinomaQingxing Liu, Jingjing Zhang, Harshad R Kulkarni, et al.
Revue Neurologique|April 15, 2008
[Primary brain stem hemorrhage: retrospective study of 25 cases]J S Raison, G Bourbotte, T P Baum, et al.
Clinical Nuclear Medicine|April 2, 2019
Prostate-Specific Membrane Antigen Accumulation in Lower Extremity LymphedemaJingjing Zhang, Harshad R Kulkarni, Aviral Singh, et al.
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|August 25, 2012
Is there a correlation between peptide receptor radionuclide therapy-associated hematological toxicity and spleen dose?Harshad R Kulkarni, Vikas Prasad, Christiane Schuchardt, et al.
World Journal of Surgery|July 23, 1998
Late results of heterotopic autotransplantation of splenic tissue into the greater omentumT Weber, E Hanisch, R P Baum, et al.
American Journal of Nuclear Medicine and Molecular Imaging|January 1, 2014
Peptide receptor radionuclide therapy of treatment-refractory metastatic thyroid cancer using (90)Yttrium and (177)Lutetium labeled somatostatin analogs: toxicity, response and survival analysisHendra Budiawan, Ali Salavati, Harshad R Kulkarni, et al.
Clinical Nuclear Medicine|December 27, 2019
Twelve-Year Survival of a Patient With Lymph Node, Pulmonary, Bone, Cardiac and Intraspinal Metastases of a Rectal Neuroendocrine Neoplasm Treated With Peptide Receptor Radionuclide Therapy-The Value of Salvage Peptide Receptor Radionuclide TherapyJingjing Zhang, Harshad R Kulkarni, Aviral Singh, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 27, 2014
PRRT: Defining the paradigm shift to achieve standardization and individualizationLisa Bodei, Mark Kidd, Richard P Baum, et al.
International Journal of Obesity and Related Metabolic Disorders : Journal of the International Association for the Study of Obesity|June 1, 1997
Removal of endogenous leptin from the circulation by the kidneyF Cumin, H P Baum, M de Gasparo, et al.
Pageof 47